Jane Street’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-194,968
| Closed | -$4.61M | – | 10347 |
|
|
2023
Q4 | $4.61M | Buy |
194,968
+136,320
| +232% | +$2.43M | ﹤0.01% | 2971 |
|
|
2023
Q3 | $874K | Buy |
58,648
+32,010
| +120% | +$424K | ﹤0.01% | 5392 |
|
|
2023
Q2 | $292K | Sell |
26,638
-544,861
| -95% | -$5.07M | ﹤0.01% | 7162 |
|
|
2023
Q1 | $4.98M | Buy |
571,499
+457,816
| +403% | +$3.66M | ﹤0.01% | 2472 |
|
|
2022
Q4 | $713K | Buy |
113,683
+102,430
| +910% | +$389K | ﹤0.01% | 5550 |
|
|
2022
Q3 | $39K | Sell |
11,253
-999
| -8% | -$3.59K | ﹤0.01% | 9016 |
|
|
2022
Q2 | $36K | Buy |
+12,252
| New | +$29.3K | ﹤0.01% | 9006 |
|
|
2021
Q3 | – | Sell |
-15,085
| Closed | -$66K | – | 10966 |
|
|
2021
Q2 | $66K | Sell |
15,085
-20,847
| -58% | -$92.4K | ﹤0.01% | 9429 |
|
|
2021
Q1 | $163K | Sell |
35,932
-76,431
| -68% | -$411K | ﹤0.01% | 8412 |
|
|
2020
Q4 | $645K | Buy |
112,363
+64,119
| +133% | +$485K | ﹤0.01% | 5349 |
|
|
2020
Q3 | $349K | Buy |
+48,244
| New | +$258K | ﹤0.01% | 5668 |
|
|
2020
Q1 | – | Sell |
-78,903
| Closed | -$155K | – | 6155 |
|
|
2019
Q4 | $155K | Buy |
+78,903
| New | +$296K | ﹤0.01% | 4786 |
|
|
2019
Q2 | – | Sell |
-32,623
| Closed | -$433K | – | 5910 |
|
|
2019
Q1 | $433K | Buy |
+32,623
| New | +$347K | ﹤0.01% | 3839 |
|
Other funds holding CBAY
Jane Street's CBAY Position: Q1 2024 in Review
Jane Street sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 194,968 shares — an estimated $4.61M sold.
Jane Street first reported a position in CBAY in Q1 2019 and held it in 13 quarters. The position peaked at $4.98M in Q1 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Jane Street reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Jane Street sold 194,968 Cymabay Therapeutics shares in Q1 2024, an estimated $4.61M.
- Jane Street first reported a position in Cymabay Therapeutics in Q1 2019 and held it in 13 quarters.
- Jane Street's Cymabay Therapeutics position peaked at $4.98M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.